JP2004529163A5 - - Google Patents
Download PDFInfo
- Publication number
- JP2004529163A5 JP2004529163A5 JP2002586908A JP2002586908A JP2004529163A5 JP 2004529163 A5 JP2004529163 A5 JP 2004529163A5 JP 2002586908 A JP2002586908 A JP 2002586908A JP 2002586908 A JP2002586908 A JP 2002586908A JP 2004529163 A5 JP2004529163 A5 JP 2004529163A5
- Authority
- JP
- Japan
- Prior art keywords
- liposome
- compound
- internalizable
- phospholipid
- liposome according
- Prior art date
- Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
- Granted
Links
- 239000002502 liposome Substances 0.000 claims 25
- 239000000463 material Substances 0.000 claims 11
- 150000003904 phospholipids Chemical class 0.000 claims 9
- 150000001875 compounds Chemical class 0.000 claims 6
- 239000002184 metal Substances 0.000 claims 5
- 150000002632 lipids Chemical class 0.000 claims 4
- 239000003607 modifier Substances 0.000 claims 4
- 230000007935 neutral effect Effects 0.000 claims 4
- -1 phosphatidylcholine compound Chemical class 0.000 claims 4
- 229930182558 Sterol Natural products 0.000 claims 3
- 150000003432 sterols Chemical class 0.000 claims 3
- 235000003702 sterols Nutrition 0.000 claims 3
- CIWBSHSKHKDKBQ-JLAZNSOCSA-N Ascorbic acid Chemical compound OC[C@H](O)[C@H]1OC(=O)C(O)=C1O CIWBSHSKHKDKBQ-JLAZNSOCSA-N 0.000 claims 2
- 239000013522 chelant Substances 0.000 claims 2
- 239000003795 chemical substances by application Substances 0.000 claims 2
- RWSXRVCMGQZWBV-WDSKDSINSA-N glutathione Chemical compound OC(=O)[C@@H](N)CCC(=O)N[C@@H](CS)C(=O)NCC(O)=O RWSXRVCMGQZWBV-WDSKDSINSA-N 0.000 claims 2
- 238000003384 imaging method Methods 0.000 claims 2
- 230000005298 paramagnetic effect Effects 0.000 claims 2
- 239000002243 precursor Substances 0.000 claims 2
- 238000002603 single-photon emission computed tomography Methods 0.000 claims 2
- 108010024636 Glutathione Proteins 0.000 claims 1
- ZWZWYGMENQVNFU-UHFFFAOYSA-N Glycerophosphorylserin Natural products OC(=O)C(N)COP(O)(=O)OCC(O)CO ZWZWYGMENQVNFU-UHFFFAOYSA-N 0.000 claims 1
- 206010061218 Inflammation Diseases 0.000 claims 1
- XUJNEKJLAYXESH-REOHCLBHSA-N L-Cysteine Chemical compound SC[C@H](N)C(O)=O XUJNEKJLAYXESH-REOHCLBHSA-N 0.000 claims 1
- 239000002616 MRI contrast agent Substances 0.000 claims 1
- 206010028980 Neoplasm Diseases 0.000 claims 1
- 238000012879 PET imaging Methods 0.000 claims 1
- 239000012190 activator Substances 0.000 claims 1
- AWUCVROLDVIAJX-UHFFFAOYSA-N alpha-glycerophosphate Natural products OCC(O)COP(O)(O)=O AWUCVROLDVIAJX-UHFFFAOYSA-N 0.000 claims 1
- 229960005070 ascorbic acid Drugs 0.000 claims 1
- 235000010323 ascorbic acid Nutrition 0.000 claims 1
- 239000011668 ascorbic acid Substances 0.000 claims 1
- 125000004432 carbon atom Chemical group C* 0.000 claims 1
- 239000003638 chemical reducing agent Substances 0.000 claims 1
- 239000002872 contrast media Substances 0.000 claims 1
- XUJNEKJLAYXESH-UHFFFAOYSA-N cysteine Natural products SCC(N)C(O)=O XUJNEKJLAYXESH-UHFFFAOYSA-N 0.000 claims 1
- 235000018417 cysteine Nutrition 0.000 claims 1
- 229960002433 cysteine Drugs 0.000 claims 1
- 229940079593 drug Drugs 0.000 claims 1
- 239000003814 drug Substances 0.000 claims 1
- 150000002190 fatty acyls Chemical group 0.000 claims 1
- 229960003180 glutathione Drugs 0.000 claims 1
- 235000003969 glutathione Nutrition 0.000 claims 1
- 239000012216 imaging agent Substances 0.000 claims 1
- 208000015181 infectious disease Diseases 0.000 claims 1
- 230000004054 inflammatory process Effects 0.000 claims 1
- 229940002612 prodrug Drugs 0.000 claims 1
- 239000000651 prodrug Substances 0.000 claims 1
- 230000002285 radioactive effect Effects 0.000 claims 1
Applications Claiming Priority (2)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| GBGB0111279.6A GB0111279D0 (en) | 2001-05-10 | 2001-05-10 | Radiolabelled liposomes |
| PCT/GB2002/002100 WO2002089771A1 (en) | 2001-05-10 | 2002-05-10 | Liposomes |
Publications (3)
| Publication Number | Publication Date |
|---|---|
| JP2004529163A JP2004529163A (ja) | 2004-09-24 |
| JP2004529163A5 true JP2004529163A5 (enExample) | 2005-12-22 |
| JP4629308B2 JP4629308B2 (ja) | 2011-02-09 |
Family
ID=9914262
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| JP2002586908A Expired - Fee Related JP4629308B2 (ja) | 2001-05-10 | 2002-05-10 | リポソーム |
Country Status (8)
| Country | Link |
|---|---|
| US (1) | US20040170560A1 (enExample) |
| EP (1) | EP1385480B1 (enExample) |
| JP (1) | JP4629308B2 (enExample) |
| AT (1) | ATE430557T1 (enExample) |
| DE (1) | DE60232237D1 (enExample) |
| ES (1) | ES2323493T3 (enExample) |
| GB (1) | GB0111279D0 (enExample) |
| WO (1) | WO2002089771A1 (enExample) |
Families Citing this family (35)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| JP5355842B2 (ja) * | 2002-12-31 | 2013-11-27 | ザイダス ビーエスヴィ ファーマ プライベート リミテッド | 非ペギレート化長循環性リポソーム |
| EP1694298B1 (en) * | 2003-11-03 | 2010-06-09 | Yissum Research Development Company, of The Hebrew University of Jerusalem | Method for selecting cationic or anionic liposomes for treatment of a mucosa membrane, and kit comprising the same |
| US8349359B2 (en) * | 2004-11-07 | 2013-01-08 | Your Energy Systems, LLC | Liposomal formulation for oral administration of glutathione (reduced) |
| US8790691B2 (en) * | 2008-05-23 | 2014-07-29 | The University Of British Columbia | Modified drugs for use in liposomal nanoparticles |
| CN108165548B (zh) * | 2008-09-22 | 2022-10-14 | 菲奥医药公司 | 减小大小的自递送RNAi化合物 |
| AR076634A1 (es) * | 2008-11-21 | 2011-06-29 | Medgenesis Therapeutix Inc | Composiciones y metodo para tratar desordenes del sistema nervioso central |
| US20100233270A1 (en) | 2009-01-08 | 2010-09-16 | Northwestern University | Delivery of Oligonucleotide-Functionalized Nanoparticles |
| US10519504B2 (en) | 2009-05-11 | 2019-12-31 | Berg Llc | Methods for treatment of oncological disorders using epimetabolic shifters, multidimensional intracellular molecules, or environmental influencers |
| US9849173B2 (en) * | 2009-07-06 | 2017-12-26 | Variation Biotechnologies Inc. | Methods for preparing vesicles and formulations produced therefrom |
| US11400058B2 (en) * | 2010-03-12 | 2022-08-02 | Berg Llc | Intravenous formulations of coenzyme Q10 (CoQ10) and methods of use thereof |
| EP2694463B8 (en) | 2011-04-04 | 2019-10-09 | Berg LLC | Treating central nervous system tumors with coenzyme q10 |
| CA2834353A1 (en) * | 2011-04-26 | 2012-11-01 | Cedars-Sinai Medical Center | Liposomal vancomycin for the treatment of mrsa infections |
| EA201490047A1 (ru) | 2011-06-17 | 2014-08-29 | Берг Ллк | Ингаляционные фармацевтические композиции |
| FR2979239A1 (fr) * | 2011-08-25 | 2013-03-01 | Trophos | Liposome comprenant au moins un derive de cholesterol |
| US20140023696A1 (en) * | 2012-07-20 | 2014-01-23 | Frederick Timothy Guilford | Treatment for idiopathic pulmonary fibrosis |
| EA032775B1 (ru) | 2013-04-08 | 2019-07-31 | Берг Ллк | Способы лечения злокачественной опухоли с использованием комбинированной терапии с коферментом q10 |
| WO2015013673A1 (en) | 2013-07-25 | 2015-01-29 | Aurasense Therapeutics, Llc | Spherical nucleic acid-based constructs as immunostimulatory agents for prophylactic and therapeutic use |
| US10568898B2 (en) * | 2013-08-13 | 2020-02-25 | Northwestern University | Lipophilic nanoparticles for drug delivery |
| WO2015035094A1 (en) | 2013-09-04 | 2015-03-12 | Berg Llc | Methods of treatment of cancer by continuous infusion of coenzyme q10 |
| MX389323B (es) | 2013-12-03 | 2025-03-20 | Univ Northwestern | Particulas liposomales, metodos para elaborarlas y sus usos. |
| US10434064B2 (en) | 2014-06-04 | 2019-10-08 | Exicure, Inc. | Multivalent delivery of immune modulators by liposomal spherical nucleic acids for prophylactic or therapeutic applications |
| KR102689262B1 (ko) | 2014-09-05 | 2024-07-30 | 피오 파마슈티칼스 코프. | Tyr 또는 mmp1을 표적화하는 핵산을 사용한 노화 및 피부 장애의 치료 방법 |
| JP6741673B2 (ja) | 2014-10-06 | 2020-08-19 | イグジキュア, インコーポレーテッドExicure, Inc. | 抗ｔｎｆ化合物 |
| WO2016085986A1 (en) | 2014-11-24 | 2016-06-02 | Northwestern University | High density lipoprptein nanoparticles for inflammation |
| CN105434368A (zh) * | 2014-11-27 | 2016-03-30 | 广州白云山明兴制药有限公司 | 一种注射用还原型谷胱甘肽及其预冻方法 |
| US10078092B2 (en) | 2015-03-18 | 2018-09-18 | Northwestern University | Assays for measuring binding kinetics and binding capacity of acceptors for lipophilic or amphiphilic molecules |
| WO2017087576A1 (en) | 2015-11-16 | 2017-05-26 | Berg Llc | Methods of treatment of temozolomide-resistant glioma using coenzyme q10 |
| KR102617833B1 (ko) | 2016-05-06 | 2023-12-27 | 엑시큐어 오퍼레이팅 컴퍼니 | 인터류킨 17 수용체 mRNA의 특이적 녹다운을 위한 안티센스 올리고뉴클레오티드 (ASO)를 제시하는 리포좀성 구형 핵산 (SNA) 구축물 |
| US11696954B2 (en) | 2017-04-28 | 2023-07-11 | Exicure Operating Company | Synthesis of spherical nucleic acids using lipophilic moieties |
| KR20200028997A (ko) | 2017-07-13 | 2020-03-17 | 노오쓰웨스턴 유니버시티 | 올리고뉴클레오타이드-작용화된 금속-유기 프레임워크 나노입자를 제조하는 일반적이고 직접적인 방법 |
| US11344497B1 (en) | 2017-12-08 | 2022-05-31 | Quicksilver Scientific, Inc. | Mitochondrial performance enhancement nanoemulsion |
| US10722465B1 (en) | 2017-12-08 | 2020-07-28 | Quicksilber Scientific, Inc. | Transparent colloidal vitamin supplement |
| US11291702B1 (en) | 2019-04-15 | 2022-04-05 | Quicksilver Scientific, Inc. | Liver activation nanoemulsion, solid binding composition, and toxin excretion enhancement method |
| US12319711B2 (en) | 2019-09-20 | 2025-06-03 | Northwestern University | Spherical nucleic acids with tailored and active protein coronae |
| US12378560B2 (en) | 2019-10-29 | 2025-08-05 | Northwestern University | Sequence multiplicity within spherical nucleic acids |
Family Cites Families (13)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| JPS6137735A (ja) * | 1984-07-31 | 1986-02-22 | Terumo Corp | ヘモグロビン含有リポソ−ムおよびその製造方法 |
| WO1990012595A1 (en) * | 1989-04-18 | 1990-11-01 | Vestar, Inc. | Liposomal targeting of ischemic tissue |
| US5013556A (en) * | 1989-10-20 | 1991-05-07 | Liposome Technology, Inc. | Liposomes with enhanced circulation time |
| US5143713A (en) * | 1990-05-30 | 1992-09-01 | Board Of Regents, The University Of Texas System | 99m Tc labeled liposomes |
| WO1994012155A1 (en) * | 1992-12-02 | 1994-06-09 | Vestar, Inc. | Antibiotic formulation and process |
| US6764693B1 (en) * | 1992-12-11 | 2004-07-20 | Amaox, Ltd. | Free radical quenching composition and a method to increase intracellular and/or extracellular antioxidants |
| GB9420390D0 (en) * | 1994-10-10 | 1994-11-23 | Nycomed Salutar Inc | Liposomal agents |
| EP0825852B1 (en) * | 1995-04-18 | 2004-07-07 | Yissum Research Development Company Of The Hebrew University Of Jerusalem | Liposome drug-loading method and composition |
| US6096336A (en) * | 1996-01-30 | 2000-08-01 | The Stehlin Foundation For Cancer Research | Liposomal prodrugs comprising derivatives of camptothecin and methods of treating cancer using these prodrugs |
| US6120800A (en) * | 1997-09-25 | 2000-09-19 | Nexstar Pharmaceuticals, Inc. | Vinca-alkaloid vesicles with enhanced efficacy and tumor targeting properties |
| JPH11171772A (ja) * | 1997-12-11 | 1999-06-29 | Sankyo Co Ltd | 抗腫瘍薬のリポソーム化製剤 |
| JP2002543134A (ja) * | 1999-04-29 | 2002-12-17 | アルザ・コーポレーション | 薬物保持率を改善するためのリポソーム組成物 |
| CA2340757A1 (en) * | 1999-07-07 | 2001-01-18 | Her Majesty The Queen As Represented By The Minister Of National Defence Of Her Majesty's Canadian Government | Delivery of liposomal-encapsulated antioxidants and applications thereof |
-
2001
- 2001-05-10 GB GBGB0111279.6A patent/GB0111279D0/en not_active Ceased
-
2002
- 2002-05-10 JP JP2002586908A patent/JP4629308B2/ja not_active Expired - Fee Related
- 2002-05-10 AT AT02769160T patent/ATE430557T1/de not_active IP Right Cessation
- 2002-05-10 DE DE60232237T patent/DE60232237D1/de not_active Expired - Lifetime
- 2002-05-10 EP EP02769160A patent/EP1385480B1/en not_active Expired - Lifetime
- 2002-05-10 US US10/477,157 patent/US20040170560A1/en not_active Abandoned
- 2002-05-10 ES ES02769160T patent/ES2323493T3/es not_active Expired - Lifetime
- 2002-05-10 WO PCT/GB2002/002100 patent/WO2002089771A1/en not_active Ceased
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| JP2004529163A5 (enExample) | ||
| Bartelds et al. | Niosomes, an alternative for liposomal delivery | |
| Celano et al. | Cytotoxic effects of gemcitabine-loaded liposomes in human anaplastic thyroid carcinoma cells | |
| JP2015502400A5 (enExample) | ||
| Jonah et al. | Tissue distribution of EDTA encapsulated within liposomes of varying surface properties | |
| Johnston et al. | Therapeutically optimized rates of drug release can be achieved by varying the drug-to-lipid ratio in liposomal vincristine formulations | |
| JP2572553B2 (ja) | リポソームへの医薬の装填方法 | |
| ES2529453T3 (es) | Nuevas composiciones de liposomas | |
| Hwang et al. | Remote loading of diclofenac, insulin and fluorescein isothiocyanate labeled insulin into liposomes by pH and acetate gradient methods | |
| Meers et al. | Phospholipid determinants for annexin V binding sites and the role of tryptophan 187 | |
| ES2323493T3 (es) | Liposomas. | |
| US5415867A (en) | High ratio active agent: lipid complex | |
| JP2011157376A (ja) | 金属イオンをローディングするリポソーム | |
| CA2467064A1 (en) | Lipid carrier compositions with enhanced blood stability | |
| HUP0303616A2 (hu) | Terápiás hatóanyag fokozott intracelluláris bejuttatására szolgáló liposzómakészítmény | |
| WO1996032930A1 (en) | Liposome drug-loading method and composition | |
| CO6260056A2 (es) | Composiciones de liposomas para administracion in vivo de compuestos de acido boronico | |
| JPH02501730A (ja) | 涙の出ない目を治療するためのリポソーム組成物 | |
| AU2076895A (en) | Liposomes | |
| WO2001076556A2 (en) | Lipid-based drug delivery systems against parasitic infections | |
| Van Der Geest et al. | Comparison of three remote radiolabelling methods for long-circulating liposomes | |
| EP1448165A2 (en) | Lipid carrier compositions and methods for improved drug retention | |
| US20100184964A1 (en) | Preparations of phospholipids and pharmaceuticals containing 5-amino salicylic acid for the treatment of inflammatory bowel disease | |
| Sharma et al. | Modulation of human ovarian tumor cell sensitivity to N-(phosphonacetyl)-L-aspartate (PALA) by liposome drug carriers | |
| JP2007513180A5 (enExample) |